FT Vest美国股票深度缓冲主动型ETF-3月 DMAR 深 沪
等待开盘 09-22 09:30:00 美东时间
45.70
+0.130
+0.29%
华盛通- 最 高45.73
- 今 开45.61
- 成交量 9224股
- 最 低 45.60
- 昨 收 45.5699
- 总市值 4.67亿
- 52周最高 45.73
- 市盈率 静 --
- 换手率 0.09%
- 52周最低 40.55
- 委 比 -20.00%
- 总股本 1022.50万
- 历史最高 45.73
- 量 比 0.89
- 振 幅 0.29%
- 历史最低 29.15
- 每 手 1
- 风险率 1.70%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多AbbVie gains EU approval for Rinvoq to treat pediatric arthritis
AbbVie (ABBV) on Tuesday said that Rinvoq is now approved in the European Union for the treatment of active polyarticular juvenile idiopathic arthritis in patients two years of age and older who have ...
今天 14:30
Avenue Supermarts Opens New D-Mart Store in Madhya Pradesh, Reaches 512 Outlets
Avenue Supermarts Ltd. ( ($IN:DMART) ) has shared an update. Avenue Supermarts ...
09-20 20:42
Avenue Supermarts Fined for Construction Non-Compliance in Bengaluru
Avenue Supermarts Ltd. ( ($IN:DMART) ) has provided an announcement. Avenue Sup...
08-26 13:52
AbbVie's Skyrizi wins EU approval for pediatric plaque psoriasis
AbbVie (ABBV) Tuesday said that the European Commission has approved Skyrizi (risankizumab) for the treatment of children and adolescents six years of age and older with moderate to severe plaque psor...
06-23 17:01
Avenue Supermarts Opens 501st DMart Store in GIFT City, Gandhinagar
Avenue Supermarts Ltd. ( ($IN:DMART) ) has issued an update. Avenue Supermarts ...
06-21 17:22
Fennec Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript
Fennec Pharmaceuticals (NASDAQ:FENC) released first-quarter financial results a...
05-14 21:32
Artiva Biotherapeutics Stock Slides Despite Positive Trial Data
Artiva Biotherapeutics shares fall after Phase 2a rheumatoid arthritis data and a $300 million private placement announcement.
05-09 00:20
Bristol Myers Squibb Says European Commission Grants Approval To Sotyktu, Alone Or In Combination With Methotrexate, For Treatment Of Active Psoriatic Arthritis In Adults
In the pivotal Phase 3 POETYK PsA clinical trials, Sotyktu demonstrated superiority compared with placebo at Week 16 across multiple endpoints, including skin and joint symptoms, with improvements in quality of life as
05-08 19:00
